Abstract
The possible role of activin in the regulation of malignant prostatic growth was studied using RNAase protection assays of activin receptors, inhibin/activin subunits and follistatin mRNAs in the human prostatic carcinoma cell lines LNCaP-FGC, -R and -LNO, in human prostatic carcinoma xenografts and in human prostatic tissue. Activin receptor types IA (ActRIA), IB (ActRIB), IIA (ActRIIA) and IIB (ActRIIB) mRNAs were generally expressed in prostate pithelial cells, with significantly lower levels of ActRIB mRNA in prostate tumour aterial when compared to non-malignant tissue (P< 0.05; Mann–Whitney U -test). Inhibin/activin βA- and βB-subunit mRNA expression was also found in prostate tissue. Androgen-independent xenografts expressed significantly lower amounts of βB-subunit mRNA when compared to androgen-dependent xenografts (P< 0.05). While βB-subunit mRNA was expressed by LNCaP-FGC and -LNO cells, virtually no expression was found in the androgen-independent LNCaP-R line. Inhibin α-subunit mRNA levels were low or undetectable in all samples investigated. Follistatin mRNA was undetectable in LNCaP-sublines, while low levels were found in prostatic tissues. In androgen-independent LNCaP-R cells, activin inhibited cell growth in a dose-dependent manner. These results suggest that prostate tumour progression is accompanied by a decrease of the inhibitory effect of locally produced activin by either a decrease in the expression of activin βB-subunit mRNA or by a decrease of ActRIB mRNA levels. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Batres Y, Zhang Z and Ying SY (1995) Expression of activins and activin receptor messenger RNAs in LNCaP cells, a human prostatic adenocarcinoma cell line. Int J Oncol 6: 1185–1188
Cárcamo J, Weis FMB, Ventura F, Wieser R, Wrana JL, Attisano L and Massagué J (1994) Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol 14: 3810–3821
Dalkin AC, Gilrain JT, Bradshaw D and Myers CE (1996) Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 137: 5230–5235
Donaldson CJ, Mathews LS and Vale WW (1992) Molecular cloning and binding properties of the human type II activin receptor. Biochem Biophys Res Commun 184: 310–316
Erba HP, Gunning P and Kedes L (1986) Nucleotide sequence of the human γ cytoskeletal actin mRNA: anomalous evolution of vertebrate non-muscle actin genes. Nucleic Acids Res 14: 5275–5294
Feng ZM, Madigan MB and Chen CLC (1993) Expression of type II activin receptor genes in the male and female reproductive tissues of the rat. Endocrinology 132: 2593–2600
Furst BA, Zhang Z and Ying SY (1995) Expression of activin and activin receptors in human prostatic carcinoma cell line DU145. Int J Oncol 7: 239–243
Gonzalez-Manchon C and Vale W (1989) Activin-A, inhibin and transforming growth factor-β modulate growth of two gonadal cell lines. Endocrinology 125: 1666–1672
Hasenson M, Hartley-Asp B, Kihlfors C, Lundin A, Gustafsson JA and Pousette A (1985) Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate 7: 183–194
Hashimoto M, Kondo S, Sakurai T, Etoh Y, Shibai H and Muramatsu M (1990) Activin/EDF as an inhibitor of neural differentiation. Biochem Biophys Res Commun 173: 193–200
Hedger MP, Drummond AE, Robertson DM, Risbridger GP and de Kretser DM (1989) Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol Cell Endocrinol 61: 133–138
Hildén K, Tuuri T, Erämaa M and Ritvos O (1994) Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor. Blood 83: 2163–2170
Hoehn W, Schröder FH, Riemann JF, Joebsis AC and Hermanek P (1980) Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate 1: 95–104
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1818
Ilio KY, Sensibar JA and Lee C (1995) Effect of TGF-β1, TGF-α, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J Androl 16: 482–490
McPherson SJ, Thomas TZ, Wang H, Gurusinghe CJ and Risbridger GP (1997) Growth inhibitory response to activin A and B by human prostate tumour cell lines, LNCaP and DU145. J Endocrinol 154: 535–545
Mason AJ, Biall HD and Seeburg PH (1986) Structure of two human ovarian inhibins. Biochem Biophys Res Commun 135: 957–964
Massagué J (1996) TGFβ signaling: receptors, transducers, and Mad proteins. Cell 85: 947–950
Mathews LS (1994) Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15: 310–325
Mayo KE, Cerelli GM, Spiess J, Rivier J, Rosenfeld MG, Evans RM and Vale W (1986) Inhibin A-subunit cDNAs from porcine ovary and human placenta. Proc Natl Acad Sci USA 83: 5849–5853
Mellor SL, Richards MG, Pedersen JS, Robertson DM and Risbridger GP (1998) Loss of expression and localization of inhibin α-subunit in high grade prostate cancer. J Clin Endocrin Metab 83: 969–975
Risbridger GP, Thomas T, Gurusinghe CJ and McFarlane JR (1996) Inhibin-related proteins in rat prostate. J Endocrinol 149: 93–99
Romijn JC, Verkoelen CF and Schröder FH (1988) Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12: 99–110
Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW and Weichselbaum RR (1991) Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 46: 31–36
Sambrook J, Fritsch EF and Maniatis T (1989). Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Press: New York
ten Dijke P, Ichijo H, Franzén P, Schulz P, Saras J, Toyoshima H, Heldin CH and Miyazono K (1993) Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 8: 2879–2887
ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin CH and Miyazono K (1994) Serine/threonine kinase receptors. Prog Growth Factor Res 5: 55–72
Thomas TZ, Chapman SM, Hong W, Gurusinghe C, Mellor SL, Fletcher R, Pedersen J and Risbridger GP (1998) Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia. Prostate 34: 34–43
van Schaik RHN, Wierikx CDJ, Looijenga LHJ, Oosterhuis JW and de Jong FH (1997) Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs. Br J Cancer 76: 1191–1198
van Steenbrugge GJ, van Uffelen CJ, Bolt J and Schröder FH (1991) The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40: 207–214
van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schröder FH and van Steenbrugge GJ (1996) Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 149: 1055–1062
Wang QF, Schneyer AL, Crowley WF and Sluss PM (1996 a) Overexpression of follistatin by a human prostate cancer cell line, PC-3. In: 10th International Congress of Endocrinology, pp 8823 (Abstract P3-276): San Francisco CA, USA
Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF, Jr. and Sluss PM (1996 b) Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 137: 5476–5483
Ying SY, Zhang Z and Xing W (1995) Expression of activin and activin receptors in PC3 human prostatic cancer cells. Int J Oncol 6: 601–606
Ying SY, Zhang Z, Batres Y, Zhao Y, Lin SL and Li G (1997) p53 is involved in the inhibition of cell proliferation mediated by activin A in cultured human prostate cancer LNCaP cells. Int J Oncol 11: 591–595
Zhang Z, Zheng J, Zhao Y, Li G, Batres Y, Luo MP, Wan M and Ying SY (1997a) Overexpression of activin A inhibits growth, induces apoptosis, and suppresses tumorigenicity in an androgen-sensitive human prostate cancer cell line LNCaP. Int J Oncol 11: 727–736
Zhang Z, Zhao Y, Batres Y, Lin MF and Ying SY (1997b) Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 234: 362–365
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
van Schaik, R., Wierikx, C., Timmerman, M. et al. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. Br J Cancer 82, 112–117 (2000). https://doi.org/10.1054/bjoc.1999.0886
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0886
Keywords
This article is cited by
-
Lentivirus-Mediated Short Hairpin RNA for Follistatin Downregulation Suppresses Tumor Progression in Hypopharyngeal Carcinoma
Current Medical Science (2022)
-
Follistatin as potential therapeutic target in prostate cancer
Targeted Oncology (2013)
-
Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression
Medical Oncology (2012)
-
Serum follistatin in patients with prostate cancer metastatic to the bone
Clinical & Experimental Metastasis (2010)